Teva Pharmaceutical Industries (MEX:TEVA N) Beneish M-Score: -2.35 (As of Jul. 06, 2026)


MEX:TEVA N Teva Pharmaceutical Industries Ltd MEX:TEVA N
40 GF Score
Price MXN597.50
GF Value MXN347.38
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Teva Pharmaceutical Industries Beneish M-Score?

Teva Pharmaceutical Industries MEX:TEVA N 40 Beneish M-Score is -2.35 as of Jul. 06, 2026. GuruFocus rates MEX:TEVA N with a GF Score™ of 40/100 and a GF Value™ of MXN347.38 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 910 Drug Manufacturers companies, Teva Pharmaceutical Industries ranks worse than 61.1% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.35 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Teva Pharmaceutical Industries's Beneish M-Score or its related term are showing as below:

MEX:TEVA N' s Beneish M-Score Range Over the Past 10 Years
Min: -2.71   Med: -2.46   Max: -2.02
Current: -2.35

During the past 13 years, the highest Beneish M-Score of Teva Pharmaceutical Industries was -2.02. The lowest was -2.71. And the median was -2.46.


Teva Pharmaceutical Industries Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Teva Pharmaceutical Industries's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Teva Pharmaceutical Industries Beneish M-Score Chart

Teva Pharmaceutical Industries Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.38 -2.58 -2.47 -2.53 -2.15

Teva Pharmaceutical Industries Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.47 -2.44 -2.25 -2.15 -2.35

MEX:TEVA N vs ZTS, UTHR, VTRS: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Teva Pharmaceutical Industries's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Teva Pharmaceutical Industries Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Teva Pharmaceutical Industries's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Teva Pharmaceutical Industries's Beneish M-Score falls into.


MEX:TEVA N
40GF Score
Teva Pharmaceutical Industries Ltd MEX:TEVA N
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Teva Pharmaceutical Industries Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Teva Pharmaceutical Industries for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9171+0.528 * 0.9449+0.404 * 0.964+0.892 * 0.9637+0.115 * 0.8793
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0384+4.679 * 0.03839-0.327 * 0.9647
=-2.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was MXN61,185 Mil.
Revenue was 71788.179 + 84824.853 + 82182.016 + 78630.739 = MXN317,426 Mil.
Gross Profit was 35560.484 + 47823.139 + 42265.037 + 39578.978 = MXN165,228 Mil.
Total Current Assets was MXN247,228 Mil.
Total Assets was MXN722,029 Mil.
Property, Plant and Equipment(Net PPE) was MXN78,136 Mil.
Depreciation, Depletion and Amortization(DDA) was MXN18,285 Mil.
Selling, General, & Admin. Expense(SGA) was MXN74,105 Mil.
Total Current Liabilities was MXN244,018 Mil.
Long-Term Debt & Capital Lease Obligation was MXN257,777 Mil.
Net Income was 6654.066 + 8642.736 + 7943.039 + 5309.834 = MXN28,550 Mil.
Non Operating Income was -1929.499 + -16493.221 + -3558.775 + -8360.165 = MXN-30,342 Mil.
Cash Flow from Operations was -721.308 + 20850.601 + 6769.01 + 4274.228 = MXN31,173 Mil.
Total Receivables was MXN69,231 Mil.
Revenue was 79602.856 + 88198.755 + 85298.38 + 76284.909 = MXN329,385 Mil.
Gross Profit was 38400.041 + 44234.94 + 42294.764 + 37079.889 = MXN162,010 Mil.
Total Current Assets was MXN235,842 Mil.
Total Assets was MXN785,902 Mil.
Property, Plant and Equipment(Net PPE) was MXN102,168 Mil.
Depreciation, Depletion and Amortization(DDA) was MXN20,447 Mil.
Selling, General, & Admin. Expense(SGA) was MXN74,052 Mil.
Total Current Liabilities was MXN228,252 Mil.
Long-Term Debt & Capital Lease Obligation was MXN337,929 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(61184.951 / 317425.787) / (69230.549 / 329384.9)
=0.192754 / 0.210181
=0.9171

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(162009.634 / 329384.9) / (165227.638 / 317425.787)
=0.491855 / 0.520524
=0.9449

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (247228.317 + 78135.689) / 722029.309) / (1 - (235842.13 + 102168.251) / 785901.754)
=0.549376 / 0.569908
=0.964

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=317425.787 / 329384.9
=0.9637

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(20446.679 / (20446.679 + 102168.251)) / (18285.132 / (18285.132 + 78135.689))
=0.166755 / 0.189639
=0.8793

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(74105.194 / 317425.787) / (74052.126 / 329384.9)
=0.233457 / 0.224819
=1.0384

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((257777.447 + 244018.497) / 722029.309) / ((337928.548 + 228252.138) / 785901.754)
=0.69498 / 0.720422
=0.9647

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(28549.675 - -30341.66 - 31172.531) / 722029.309
=0.03839

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Teva Pharmaceutical Industries has a M-score of -2.46 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.35 mean?
Teva Pharmaceutical Industries (MEX:TEVA N) has a Beneish M-Score of -2.35 as of Jul. 06, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Teva Pharmaceutical Industries and its competitors. According to the industry distribution chart, Teva Pharmaceutical Industries ranks #556 out of 910 companies in the Drug Manufacturers industry, placing it in the top 61.1%.
Is Teva Pharmaceutical Industries' Beneish M-Score too high?
Teva Pharmaceutical Industries' current Beneish M-Score is -2.35. Based on the distribution chart, Teva Pharmaceutical Industries ranks #556 out of 910 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Teva Pharmaceutical Industries has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Teva Pharmaceutical Industries' Beneish M-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Teva Pharmaceutical Industries ranks #556 out of 910 companies for Beneish M-Score. This places Teva Pharmaceutical Industries in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Teva Pharmaceutical Industries and its competitors. Teva Pharmaceutical Industries's current Beneish M-Score is -2.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Teva Pharmaceutical Industries stock overvalued right now?
Based on GuruFocus' analysis, Teva Pharmaceutical Industries (MEX:TEVA N) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN347.38, compared to a current price of MXN597.50 — trading 72% above its estimated fair value. The current Beneish M-Score is -2.35. Teva Pharmaceutical Industries' overall GF Score™ is 40/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Teva Pharmaceutical Industries (MEX:TEVA N), the current Beneish M-Score is -2.35 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Teva Pharmaceutical Industries (MEX:TEVA N) Overvalued in 2026?

Based on GuruFocus' analysis, Teva Pharmaceutical Industries stock appears to be overvalued. The current stock price of MXN597.50 is trading 72% above its estimated GF Value™ of MXN347.38. GuruFocus considers Teva Pharmaceutical Industries to be Significantly Overvalued.

Key valuation signals for MEX:TEVA N:

  • Beneish M-Score: -2.35
  • GF Value™: MXN347.38 vs. price of MXN597.50 (72% above fair value)
  • GF Score™: 40/100 with 5 warning signs

No single metric tells the full story. See the MEX:TEVA N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Teva Pharmaceutical Industries Business Description

Address 124 Dvora HaNevi’a Street, Tel Aviv, ISR, 6944020
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
40GF Score

Get the complete analysis for MEX:TEVA N

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN597.50
Price
MXN347.38
GF Value